Inicio › Cáncer de mama triple negativo › California

Ensayos clínicos de Cáncer de mama triple negativo en California

53 estudios sobre Cáncer de mama triple negativo buscan participantes en California.

Ciudades en California

Texto oficial del estudio (inglés)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

City of Hope National Medical Center, Duarte
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
UCLA Department of Medicine-Hematology/Oncology, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

University of San Diego Moores Cancer Center, La Jolla
UCLA Jonsson Comprehensive Cancer Center, Los Angeles
USC Norris Comprehensive Cancer Center, Los Angeles

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

University of California - Los Angeles, Los Angeles

ReclutandoFase 1

Edades de 19 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06586957

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

University of California San Diego, La Jolla
Stanford University, Palo Alto
UCLA Medical Center, Santa Monica

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04981119

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

City of Hope ( Site 0097), Duarte
City of Hope Lennar Foundation Cancer Center ( Site 0099), Irvine
UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06841354

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

MemorialCare Orange Coast Medical Center ( Site 9501), Fountain Valley
Scripps Cancer Center ( Site 0052), La Jolla
Kaiser Permanente - Oakland ( Site 0079), Oakland
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06393374

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank
Community Cancer Institute ( Site 0100), Clovis
Providence Medical Foundation ( Site 0080), Fullerton
y 4 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06966700

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Kivu Trial Site, Santa Monica

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT07229313

Intratumoral N17350 in Advanced Solid Tumors

The Angeles Clinic and Research Institute, Los Angeles
UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Scripps Clinic Torrey Pines - La Jolla, San Diego
y 1 más

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07339176

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Beverly Hills Cancer Center, Beverly Hills
City of Hope Cancer Center, Duarte
University of California Irvine Medical Center, Orange
y 1 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT05983432

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

City of Hope, Duarte
Hoag Memorial Hospital Presbyterian, Irvine

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07020117

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Ellison Institute of Technology (EITM), Los Angeles

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT06353997

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Alta Bates Summit Medical Center, Berkeley
PIH Health Whittier Hospital, Downey
Cedars-Sinai Cancer at Beverly Hills, Los Angeles
y 6 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT05633654

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06400472

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

PIH Health Whittier Hospital, Whittier

ReclutandoEstudio observacional

Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07211178

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

City of Hope, Duarte
UC San Diego Moores Cancer Center, La Jolla

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07029399

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Community Cancer Institute, Clovis
USC/Norris Comprehensive Cancer Center, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT04895709

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center, Los Angeles

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 ago 2026 · NCT05985655

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Stanford University, Stanford

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT04768426

SMP-3124LP in Adults With Advanced Solid Tumors

Cedars Sinai Medical Center, Los Angeles

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT06526819

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

City of Hope at Arcadia, Arcadia
City of Hope Medical Center, Duarte
City of Hope at Seacliff, Huntington Beach
y 8 más

Reclutando

Edades de 18 en adelante · Mujeres · Actualizado el 10 ago 2026 · NCT07741968

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Helios Clinical Research, Cerritos
USC/Norris Comprehensive Cancer Center, Los Angeles
Valkyrie Clinical Trials, Los Angeles
y 2 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT06926868

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Cedars-Sinai Medical Center, Los Angeles

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT05318469

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

University of California Los Angeles Medical Center, Los Angeles
University of California, San Diego; Moores Cancer Center, San Diego
USOR Sansum Clinic, Santa Barbara
y 1 más

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT05579366

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Cedars-Sinai Medical Center, Los Angeles
Cedars-Sinai Medical Center Beverly Hills, Los Angeles
Huntington Cancer Center, an Affiliate of CS Cancer, Pasadena
y 1 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07017673

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

University of California LA, Los Angeles
Stanford University Medical Center, Palo Alto

ReclutandoFase 1

Edades de 18 a 100 · Todos los sexos · Actualizado el 29 jul 2026 · NCT06562192

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
University of California Davis Comprehensive Cancer Center, Sacramento
y 1 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT05208762

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT07318805

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Chao Family Comprehensive Cancer Center University of California, Irvine, Orange

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jul 2026 · NCT07064018

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
UCLA David Geffen School of Medicine, Division of Hematology/Oncology, Santa Monica

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT05377996

A Study of LY4175408 in Participants With Advanced Cancer

Stanford Medicine Cancer Center, Stanford

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT07046923

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

City of Hope National Medical Center /ID# 276272, Duarte
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT05005403

Study of XB010 in Subjects With Solid Tumors

City of Hope Orange County Lennar Foundation Cancer Center, Irvine
UCLA Department of Medicine - Hematology/Oncology, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jun 2026 · NCT06545331

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

University of California, San Francisco, San Francisco

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 jun 2026 · NCT06224673

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Start Lacn, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT07517198

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Stanford Women's Cancer Center, Palo Alto

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT04300556

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

USC / Norris Comprehensive Cancer Center, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Mujeres · Actualizado el 19 may 2026 · NCT05989828

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of California - Davis, Comprehensive Cancer Center, Davis
City of Hope, Duarte
University of California San Diego, La Jolla
y 3 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 may 2026 · NCT01042379

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

University of California San Francisco, San Francisco

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 may 2026 · NCT04434040

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center, Los Angeles

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 20 abr 2026 · NCT05491226

De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.